This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Steinhubl, S. R. Articles by Topol, E. J. Search for Related Content PubMed PubMed Citation Articles by Steinhubl, S. R. Articles by Topol, E. J.

The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non–Q-wave myocardial infarctions

Steven R. Steinhubl, MD^* , Michael S. Lauer, MD, FACC^*, Debabrata P. Mukherjee, MD^*, David J. Moliterno, MD, FACC^*, A. Michael Lincoff, MD, FACC^*, Stephen G. Ellis, MD, FACC^* and Eric J. Topol, MD, FACC^*

^* Department of Cardiology and Joseph J. Jacobs Center for Thrombosis and Vascular Biology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
Department of Medicine, Ohio State University, Cleveland, Ohio, USA

View larger version (12K): [in a new window]   Figure 1 Incidence of procedure-related non–Q-wave MI in patient groups based on the duration of ticlopidine pretreatment. Chi-squared for trend, p = 0.002.